Takeda, Seattle Genetics Drug Shown Effective Against Lymphoma
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and U.S.-based Seattle Genetics plan to ask the FDA for accelerated approval of their Hodgkin's lymphoma drug based on better-than-expected trial results and the fact that it addresses an unmet medical need